Literature DB >> 35512377

Combat-Related Invasive Fungal Wound Infections.

Ret Carlos J Rodriguez1, Anuradha Ganesan2,3,4, Faraz Shaikh2,3, M Leigh Carson2,3, William Bradley2,3, Tyler E Warkentien4, David R Tribble2.   

Abstract

INTRODUCTION: During Operation Enduring Freedom in Afghanistan, an outbreak of combat-related invasive fungal wound infections (IFIs) emerged among casualties with dismounted blast trauma and became a priority issue for the Military Health System.
METHODS: In 2011, the Trauma Infectious Disease Outcomes Study (TIDOS) team led the Department of Defense IFI outbreak investigation to describe characteristics of IFIs among combat casualties and provide recommendations related to management of the disease. To support the outbreak investigation, existing IFI definitions and classifications utilized for immunocompromised patients were modified for use in epidemiologic research in a trauma population. Following the conclusion of the outbreak investigation, multiple retrospective analyses using a population of 77 IFI patients (injured during June 2009 to August 2011) were conducted to evaluate IFI epidemiology, wound microbiology, and diagnostics to support refinement of Joint Trauma System (JTS) clinical practice guidelines. Following cessation of combat operations in Afghanistan, the TIDOS database was comprehensively reviewed to identify patients with laboratory evidence of a fungal infection and refine the IFI classification scheme to incorporate timing of laboratory fungal evidence and include categories that denote a high or low level of suspicion for IFI. The refined IFI classification scheme was utilized in a large-scale epidemiologic assessment of casualties injured over a 5.5-year period.
RESULTS: Among 720 combat casualties admitted to participating hospitals (2009-2014) who had histopathology and/or wound cultures collected, 94 (13%) met criteria for an IFI and 61 (8%) were classified as high suspicion of IFI. Risk factors for development of combat-related IFIs include sustaining a dismounted blast injury, experiencing a traumatic transfemoral amputation, and requiring resuscitation with large-volume (>20 units) blood transfusions. Moreover, TIDOS analyses demonstrated the adverse impact of IFIs on wound healing, particularly with order Mucorales. A polymerase chain reaction (PCR)-based assay to identify filamentous fungi and support earlier IFI diagnosis was also assessed using archived formalin-fixed, paraffin-embedded tissue specimens. Although the PCR-based assay had high specificity (99%), there was low sensitivity (63%); however, sensitivity improved to 83% in tissues collected from sites with angioinvasion. Data obtained from the initial IFI outbreak investigation (37 IFI patients) and subsequent TIDOS analyses (77 IFI patients) supported development and refinement of a JTS clinical practice guideline for the management of IFIs in war wounds. Furthermore, a local clinical practice guideline to screen for early tissue-based evidence of IFIs among blast casualties at the Landstuhl Regional Medical Center was critically evaluated through a TIDOS investigation, providing additional clinical practice support. Through a collaboration with the Uniformed Services University Surgical Critical Care Initiative, findings from TIDOS analyses were used to support development of a clinical decision support tool to facilitate early risk stratification.
CONCLUSIONS: Combat-related IFIs are a highly morbid complication following severe blast trauma and remain a threat for future modern warfare. Our findings have supported JTS clinical recommendations, refined IFI classification, and confirmed the utility of PCR-based assays as a complement to histopathology and/or culture to promote early diagnosis. Analyses underway or planned will add to the knowledge base of IFI epidemiology, diagnostics, prevention, and management. Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Year:  2022        PMID: 35512377      PMCID: PMC9278336          DOI: 10.1093/milmed/usab074

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.563


  46 in total

1.  Invasive mucormycosis and aspergillosis in a healthy 22-year-old battle casualty: case report.

Authors:  Jason S Radowsky; Alan A Strawn; Jeffrey Sherwood; Adam Braden; William Liston
Journal:  Surg Infect (Larchmt)       Date:  2011-10-17       Impact factor: 2.150

2.  Pythium aphanidermatum infection following combat trauma.

Authors:  Tatjana P Calvano; Peter J Blatz; Todd J Vento; Brian L Wickes; Deanna A Sutton; Elizabeth H Thompson; Christopher E White; Evan M Renz; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

3.  Treatment of Suspected Invasive Fungal Infection in War Wounds.

Authors:  Carlos J Rodriguez; David R Tribble; Debra L Malone; Clinton K Murray; Elliot M Jessie; Mansoor Khan; Mark E Fleming; Benjamin K Potter; Wade T Gordon; Stacy A Shackelford
Journal:  Mil Med       Date:  2018-09-01       Impact factor: 1.437

Review 4.  Epidemiology of mucormycosis in Europe.

Authors:  G Petrikkos; A Skiada; M Drogari-Apiranthitou
Journal:  Clin Microbiol Infect       Date:  2014-03-06       Impact factor: 8.067

Review 5.  Histopathologic diagnosis of fungal infections in the 21st century.

Authors:  Jeannette Guarner; Mary E Brandt
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  Invasive mold infections following combat-related injuries.

Authors:  Tyler Warkentien; Carlos Rodriguez; Bradley Lloyd; Justin Wells; Amy Weintrob; James R Dunne; Anuradha Ganesan; Ping Li; William Bradley; Lakisha J Gaskins; Françoise Seillier-Moiseiwitsch; Clinton K Murray; Eugene V Millar; Bryan Keenan; Kristopher Paolino; Mark Fleming; Duane R Hospenthal; Glenn W Wortmann; Michael L Landrum; Mark G Kortepeter; David R Tribble
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

Review 7.  Cutaneous mucormycosis secondary to penetrative trauma.

Authors:  Bilal Zahoor; Stephen Kent; Daryl Wall
Journal:  Injury       Date:  2016-04-11       Impact factor: 2.586

8.  Early Complications and Outcomes in Combat Injury-Related Invasive Fungal Wound Infections: A Case-Control Analysis.

Authors:  Louis R Lewandowski; Amy C Weintrob; David R Tribble; Carlos J Rodriguez; Joseph Petfield; Bradley A Lloyd; Clinton K Murray; Daniel Stinner; Deepak Aggarwal; Faraz Shaikh; Benjamin K Potter
Journal:  J Orthop Trauma       Date:  2016-03       Impact factor: 2.512

9.  Mucormycosis attributed mortality: a seven-year review of surgical and medical management.

Authors:  Thomas A Mitchell; Mark O Hardin; Clinton K Murray; John D Ritchie; Leopoldo C Cancio; Evan M Renz; Christopher E White
Journal:  Burns       Date:  2014-05-29       Impact factor: 2.744

10.  Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data.

Authors:  Marya D Zilberberg; Andrew F Shorr; Huan Huang; Paresh Chaudhari; Victoria Federico Paly; Joseph Menzin
Journal:  BMC Infect Dis       Date:  2014-06-05       Impact factor: 3.090

View more
  3 in total

1.  IDCRP Trauma-Related Infection Research.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

Review 2.  Multidrug-Resistant and Virulent Organisms Trauma Infections: Trauma Infectious Disease Outcomes Study Initiative.

Authors:  Katrin Mende; Kevin S Akers; Stuart D Tyner; Jason W Bennett; Mark P Simons; Dana M Blyth; Ping Li; Laveta Stewart; David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

Review 3.  Department of Defense Trauma Registry Infectious Disease Module Impact on Clinical Practice.

Authors:  David R Tribble; Mary Ann Spott; Stacey A Shackleford; Jennifer M Gurney; Bg Clinton K Murray
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.